DGAP-News: Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology
(firmenpresse) - DGAP-News: Evotec AG / Key word(s): Agreement
Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec
establish collaboration in oncology
30.04.2013 / 07:26
---------------------------------------------------------------------
* Collaboration to discover new oncology therapies targeting epigenetic
mechanisms
Hamburg, Germany and Boston, MA - 30 April 2013: The Belfer Institute for
Applied Cancer Science at Dana-Farber Cancer Institute and Evotec AG
(Frankfurt Stock Exchange: EVT, TecDAX, ISIN: DE0005664809) today announced
a research collaboration aimed at discovering and commercialising novel
cancer treatments based on epigenetic drug mechanisms.
The goal of the collaboration is to validate emerging epigenetic targets
for oncology indications and to demonstrate the drugability of the selected
target families. Evotec, Dana-Farber and Dana-Farber's Belfer Institute for
Applied Cancer Science will invest in enabling technologies, experimental
target validation and the generation of chemical matter by leveraging
existing expertise and platforms. The collaboration will be fuelled by
substantial scientific contributions from the three organisations aligned
on the objective to develop therapies that address unmet medical needs for
cancer patients.
Epigenetics is a rapidly evolving high potential field of pharmaceutical
research, calling for close relationships between academia and
biotechnology innovators. By combining the complimentary capabilities of
Dana-Farber, the Belfer Institute for Applied Cancer Science and Evotec
this collaboration is uniquely positioned to succeed.
'We are very proud to have entered into this collaboration with Dana-Farber
and the Belfer Institute for Applied Cancer Science, which perfectly
matches our innovation strategy as described in Evotec's Action Plan 2016',
said Dr Werner Lanthaler, CEO of Evotec. 'We are enthusiastic about
exploring novel targets that have the potential to produce first-in-class
therapeutics for the treatment of cancer.'
Dr Jessie English, Head of Research at the Belfer Institute for Applied
Cancer Science, added:'This pioneering partnership provides a unique
opportunity to combine Evotec's drug discovery capabilities with Belfer
Institute for Applied Cancer Science and Dana-Farber Cancer Institute's
expertise in oncology disease biology to accelerate the development of new
medicines for patients.'
Further details and commercial terms of the cooperation are not disclosed.
ABOUT DANA-FARBER CANCER INSTITUTE
Dana-Farber Cancer Institute (www.dana-farber.org) is a principal teaching
affiliate of the Harvard Medical School and is among the leading cancer
research and care centers in the United States. It is a founding member of
the Dana-Farber/Harvard Cancer Center (DF/HCC), designated a comprehensive
cancer center by the National Cancer Institute. It provides adult cancer
care with Brigham and Women's Hospital as Dana-Farber/Brigham and Women's
Cancer Center and it provides pediatric care with Boston Children's
Hospital as Dana-Farber/Children's Hospital Cancer Center. Dana-Farber is
the top ranked cancer center in New England, according to U.S. News&World
Report, and one of the largest recipients among independent hospitals of
National Cancer Institute and National Institutes of Health grant funding.
Follow Dana-Farber on Facebook: www.facebook.com/danafarbercancerinstitute
and on Twitter: (at)danafarber.
ABOUT EVOTEC AG
Evotec is a drug discovery alliance and development partnership company
focused on rapidly progressing innovative product approaches with leading
pharmaceutical and biotechnology companies. We operate worldwide providing
the highest quality stand-alone and integrated drug discovery solutions,
covering all activities from target-to-clinic. The Company has established
a unique position by assembling top-class scientific experts and
integrating state-of-the-art technologies as well as substantial experience
and expertise in key therapeutic areas including neuroscience, pain,
metabolic diseases as well as oncology and inflammation. Evotec has
long-term discovery alliances with partners including Bayer, Boehringer
Ingelheim, CHDI, Genentech, Janssen Pharmaceuticals, MedImmune/AstraZeneca
and Ono Pharmaceutical. In addition, the Company has existing development
partnerships and product candidates both in clinical and pre-clinical
development. These include partnerships with Boehringer Ingelheim,
MedImmune and Andromeda (Teva) in the field of diabetes, with Janssen
Pharmaceuticals in the field of depression and with Roche in the field of
Alzheimer's disease. For additional information please go to
www.evotec.com.
ABOUT EPIGENETICS
In biology, and specifically genetics, epigenetics is the study of changes
in gene expression or cellular phenotype, caused by mechanisms other than
changes in the underlying DNA sequence - hence the name epi- (Greek:???-
over, above, outer) -genetics, some of which are heritable. It refers to
functionally relevant modifications to the genome that do not involve a
change in the nucleotide sequence. Examples of such modifications are DNA
methylation and histone modification, both of which serve to regulate gene
expression without altering the underlying DNA sequence.
(Source:Wikipedia.org/wiki/Epigenetics)
Contact Evotec AG:
Gabriele Hansen, Head of Corporate Communications, Phone:
+49.(0)40.56081-255, gabriele.hansen(at)evotec.com
FORWARD LOOKING STATEMENTS - Information set forth in this press release
contains forward-looking statements, which involve a number of risks and
uncertainties. The forward-looking statements contained herein represent
the judgement of Evotec as of the date of this report. Such forward-looking
statements are neither promises nor guarantees, but are subject to a
variety of risks and uncertainties, many of which are beyond our control,
and which could cause actual results to differ materially from those
contemplated in these forward-looking statements. We expressly disclaim any
obligation or undertaking to release publicly any updates or revisions to
any such statements to reflect any change in our expectations or any change
in events, conditions or circumstances on which any such statement is
based.
End of Corporate News
---------------------------------------------------------------------
30.04.2013 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Evotec AG
Manfred Eigen Campus / Essener Bogen 7
22419 Hamburg
Germany
Phone: +49 (0)40 560 81-0
Fax: +49 (0)40 560 81-222
E-mail: info(at)evotec.com
Internet: www.evotec.com
ISIN: DE0005664809
WKN: 566480Indices: TecDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Hannover,
München, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
209045 30.04.2013
Themen in dieser Pressemitteilung:
dana
farber-s-belfer-institute-for-applied-cancer-science-and-evotec-establish-collaboration-in-oncology
Unternehmensinformation / Kurzprofil:
Datum: 30.04.2013 - 07:26 Uhr
Sprache: Deutsch
News-ID 254132
Anzahl Zeichen: 11625
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 288 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Dana-Farber's Belfer Institute for Applied Cancer Science and Evotec establish collaboration in oncology"
steht unter der journalistisch-redaktionellen Verantwortung von
Evotec AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
